Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12690256 | 0.80 | HCAR3 (0.34) | HCAR3 | |
| SCHEMBL20333838 | 0.79 | IDH1 (0.37) | TRPV4HCRTR1BCDIN3DTRPV1 | |
| SCHEMBL18372787 | 0.78 | TRPV4 (0.39) | TRPV4KDM4EHCRTR1MAPTBCDIN3D | |
| SCHEMBL16626827 | 0.78 | HCAR3 (0.44) | KDM4EMAPTEGFRHCAR3 | |
| SCHEMBL24527461 | 0.75 | HRH3 (0.39) | KDM4EHCRTR1BCDIN3DHCAR3 | |
| SCHEMBL13117743 | 0.75 | HDAC4 (0.52) | KDM4EHCRTR1GAA | |
| SCHEMBL30658431 | 0.74 | KDM4E (0.41) | KDM4EHCRTR1BCDIN3DHCAR3 | |
| SCHEMBL19203407 | 0.74 | KDM4E (0.41) | KDM4EHCRTR1BCDIN3DHCAR3 | |
| SCHEMBL19203405 | 0.74 | KDM4E (0.41) | KDM4EHCRTR1BCDIN3DHCAR3 | |
| SCHEMBL116298 | 0.72 | RAB9A (0.49) | MAPTEGFRGAAHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008768-A1 | UREA DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20090270416-A1 | N-OXIDES OF DIARYLUREA DERIVATIVES AND THEIR USE AS Chk1 INHIBITORS FOR THE TREATMENT OF CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008768-A1 | UREA DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NOD1, NLRP3, NOD2 | TRPV4 2919/4885KDM4E 4547/4885HCRTR1 782/4885 |
| US-20090270416-A1 | N-OXIDES OF DIARYLUREA DERIVATIVES AND THEIR USE AS Chk1 INHIBITORS FOR THE TREATMENT OF CANCER | CHEK1, CHEK2, CDK1 | TRPV4 3614/4885KDM4E 735/4885HCRTR1 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.